Indeed, CYPA2 is downregulated, whereas CYP2E1 and the efflux transporter MRP3 are upregulated, potentially inducing high variability in the OAC bioavailability in patients with NAFLD (11, 42). The gene discussed is CYP2E1; the disease is metabolic dysfunction-associated steatotic liver disease.